Expertise in
18
conditions

Carmine Selleri

Universita Degli Studi Di Modena E Reggio Emilia
Modena, IT 
Expertise in
18
conditions
Universita Degli Studi Di Modena E Reggio Emilia
Modena, IT 

Overview

Carmine Selleri practices practicing medicine in Modena, Italy.

Mr. Selleri is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Severe Acute Respiratory Syndrome (SARS), Cytomegalovirus Infection, Nodular Nonsuppurative Panniculitis, Bone Marrow Transplant, and Splenectomy.

He is actively involved in clinical research, co-authoring 174 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Universita degli Studi di Modena e Reggio Emilia
Modena, Italy
Other Locations
Hematology Branch, Bethesda, MD

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drugs: R2-MANT, R-MANT
Study Phase: Phase 3
A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients With B-Cell Acute Lymphoblastic Leukemia With Positive Minimal Residual Disease Before Any Hematopoietic Stem Cell Transplantation
A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients With B-Cell Acute Lymphoblastic Leukemia With Positive Minimal Residual Disease Before Any Hematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Drug
Study Drug: Inotuzumab
Study Phase: Phase 2
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
Study Phase: Phase 3
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
Enrollment Status: Completed
Publish Date: November 25, 2022
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

174 Total Publications

Cutaneous Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Cohort Study of Clinical Spectrum and Treatment Patterns.
Cutaneous Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Cohort Study of Clinical Spectrum and Treatment Patterns.
Journal: Life (Basel, Switzerland)
Published: July 08, 2026

Frequently Asked Questions about Carmine Selleri

Is Carmine Selleri a top-rated expert for Severe Acute Respiratory Syndrome (SARS)?

MediFind is an objective health platform that identifies experts based on real-world data. Carmine Selleri is classified as an Distinguished expert for Severe Acute Respiratory Syndrome (SARS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Carmine Selleri participate in research or clinical trials?

Yes. Carmine Selleri has published 174 articles and abstracts on conditions like Severe Acute Respiratory Syndrome (SARS). You can view a list of Carmine Selleri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Selleri's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile